vs
Side-by-side financial comparison of Cheche Group Inc. (CCG) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Cheche Group Inc. is the larger business by last-quarter revenue ($32.8M vs $20.4M, roughly 1.6× Sight Sciences, Inc.). Cheche Group Inc. runs the higher net margin — 0.5% vs -20.4%, a 20.9% gap on every dollar of revenue.
Cheche Group Inc. is a leading automotive digital service provider headquartered in China. It offers integrated solutions including auto insurance intermediary services, smart auto after-sales support, and connected vehicle technology products, serving individual car owners, auto dealerships, and insurance partners across domestic and select Southeast Asian markets.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CCG vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $32.8M | $20.4M |
| Net Profit | $153.6K | $-4.2M |
| Gross Margin | 5.7% | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 0.5% | -20.4% |
| Revenue YoY | — | 6.9% |
| Net Profit YoY | — | 64.9% |
| EPS (diluted) | $0.00 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $32.8M | — | ||
| Q4 25 | — | $20.4M | ||
| Q3 25 | — | $19.9M | ||
| Q2 25 | $26.0M | $19.6M | ||
| Q1 25 | — | $17.5M | ||
| Q4 24 | $18.6M | $19.1M | ||
| Q3 24 | — | $20.2M | ||
| Q2 24 | $36.1M | $21.4M |
| Q1 26 | $153.6K | — | ||
| Q4 25 | — | $-4.2M | ||
| Q3 25 | — | $-8.2M | ||
| Q2 25 | $-492.4K | $-11.9M | ||
| Q1 25 | — | $-14.2M | ||
| Q4 24 | $-196.7K | $-11.8M | ||
| Q3 24 | — | $-11.1M | ||
| Q2 24 | $-7.6M | $-12.3M |
| Q1 26 | 5.7% | — | ||
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | 4.9% | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | 5.2% | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | 4.3% | 85.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | -18.0% | ||
| Q3 25 | — | -39.7% | ||
| Q2 25 | -2.0% | -59.6% | ||
| Q1 25 | — | -79.2% | ||
| Q4 24 | -0.3% | -62.5% | ||
| Q3 24 | — | -55.7% | ||
| Q2 24 | -4.7% | -59.2% |
| Q1 26 | 0.5% | — | ||
| Q4 25 | — | -20.4% | ||
| Q3 25 | — | -41.0% | ||
| Q2 25 | -1.9% | -61.0% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | -1.1% | -62.1% | ||
| Q3 24 | — | -54.9% | ||
| Q2 24 | -21.0% | -57.7% |
| Q1 26 | $0.00 | — | ||
| Q4 25 | — | $-0.07 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | $-0.01 | $-0.23 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | $-0.00 | $-0.23 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.0M | $92.0M |
| Total DebtLower is stronger | $193.3K | $42.4M |
| Stockholders' EquityBook value | — | $63.9M |
| Total Assets | $203.5M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $20.0M | — | ||
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | $23.1M | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | $21.1M | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | $28.2M | $118.2M |
| Q1 26 | $193.3K | — | ||
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | $690.0K | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $63.9M | ||
| Q3 25 | — | $64.3M | ||
| Q2 25 | $47.1M | $70.0M | ||
| Q1 25 | — | $77.6M | ||
| Q4 24 | $49.1M | $87.5M | ||
| Q3 24 | — | $95.0M | ||
| Q2 24 | $48.6M | $101.6M |
| Q1 26 | $203.5M | — | ||
| Q4 25 | — | $115.3M | ||
| Q3 25 | — | $116.3M | ||
| Q2 25 | $177.3M | $122.0M | ||
| Q1 25 | — | $129.7M | ||
| Q4 24 | $177.7M | $142.8M | ||
| Q3 24 | — | $143.6M | ||
| Q2 24 | $139.3M | $149.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | 0.01× | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-8.7M | ||
| Q2 25 | $-44.7M | $-7.5M | ||
| Q1 25 | — | $-11.6M | ||
| Q4 24 | $-15.8M | $-3.5M | ||
| Q3 24 | — | $362.0K | ||
| Q2 24 | $-1.0K | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | — | $-7.8M | ||
| Q1 25 | — | — | ||
| Q4 24 | $-16.0M | $-3.6M | ||
| Q3 24 | — | $311.0K | ||
| Q2 24 | $-1.1K | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | -9.7% | ||
| Q3 25 | — | -44.7% | ||
| Q2 25 | — | -39.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | -85.9% | -18.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | -0.0% | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 1.2% | 0.7% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 0.0% | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCG
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
